Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies

• Published in: Cardiology and Therapy Vol. 13; no. 4; pp. 775 - 796
• Main Authors: Chin, Kelly M., Channick, Richard, Kim, Nick H., Ong, Rose, Turricchia, Stefano, Martin, Nicolas, Mitchell, Lada, McLaughlin, Vallerie V.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.12.2024; Springer; Adis, Springer Healthcare
• Subjects: Cardiology; Care and treatment; Causes of; Complications and side effects; Congenital heart disease; Internal Medicine; Macitentan; Medicine; Medicine & Public Health; NCT; NCT03197688; Original Research; Pulmonary arterial hypertension; Pulmonary hypertension; Real-world evidence; United States; Macitentan; Congenital heart disease; Pulmonary arterial hypertension; Real-world evidence

Introduction Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) are scarce. The OPUS/OrPHeUS studies enrolled patients with PAH newly initiating macitentan, including those with PAH associated with C...